NCT00163540

Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: —
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 17 Years – 66 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to investigate the immunogenicity and safety of a third vaccination with FSME-IMMUN 0.5 ml given approximately 12 months after the second vaccination in Study 225. In Study 225, two vaccinations were given using a rapid immunization schedule 12 ± 2 days apart.

Conditions

• Encephalitis, Tick-borne

Interventions

Type	Name	Description
BIOLOGICAL	Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

Timeline

• Start date: 2005-05-01
• Completion: 2005-06-01
• First posted: 2005-09-14
• Last updated: 2015-05-21

Locations

1 site across 1 country: Belgium